Senti Biosciences is trading at $0.23, down -12.93%, during live trading on October 16; no specific catalyst for the decline has been established.
- Shareholders approved the merger and authorized a discretionary 1-for-20 to 1-for-50 reverse split on October 15; available reporting does not link either approval to the October 16 drop.
- The biotech sector is reported higher, while broader market indicators are mixed.